0001159036-26-000024
SEC filingHalozyme Therapeutics, Inc. reported strong financial performance for the fiscal year ended December 31, 2025, with total revenues reaching $1.40 billion. The company achieved significant profitability, reporting operating income of $469.0 million and net income of $316.9 million, resulting in basic and diluted earnings per share of $3.00. Operating performance was impacted by substantial one-time expenses, including $284.9 million for acquired in-process research and development and a $48.7 million impairment of intangible assets. Despite these charges, the company demonstrated robust cash generation, with net cash provided by operating activities totaling $651.6 million. The balance sheet reflects a highly leveraged position following strategic acquisitions, with long-term debt of $2.14 billion against total stockholders' equity of $48.8 million. Total assets grew to $2.53 billion, bolstered by $580.4 million in goodwill and $981.5 million in intangible assets. The company actively managed its capital structure through debt refinancing and share repurchases totaling $342.4 million during the period.
Halozyme Therapeutics demonstrated robust financial execution in FY 2025, generating total revenues of $1.40 billion. The company successfully converted revenue into bottom-line results, achieving net income of $316.9 million and earnings per share of $3.00 on both a basic and diluted basis. Operating income stood at $469.0 million, reflecting an operating margin of approximately 33.5%. The income statement was notably impacted by non-recurring items, specifically $284.9 million in acquired in-process research and development expenses and a $48.7 million impairment charge on intangible assets. Excluding these significant one-time costs, underlying operational profitability would have been considerably higher, underscoring the strength of the core business model.
The XBRL financial data provided reports total revenues of $1.40 billion for the fiscal year. Detailed segment breakdowns regarding specific product sales, royalties, or collaborative agreement revenues were not explicitly itemized in the provided data extracts. However, the substantial revenue base supports the company's continued investment in research and development ($81.5 million) and selling, general, and administrative functions ($207.1 million). The cost of sales was reported at $228.8 million. The lack of granular segment data in the provided context limits a deeper dive into specific growth drivers, but the aggregate figure indicates a solid revenue foundation for the period.
The company maintained a healthy operating margin of 33.5% despite incurring substantial acquisition-related charges. Total operating expenses reached $927.6 million, heavily influenced by the $284.9 million acquired in-process R&D expense and $76.7 million in amortization of intangibles. The gross profit position is implied to be strong given the cost of sales of $228.8 million against $1.40 billion in revenue, suggesting a gross margin exceeding 80%, characteristic of a high-value biopharmaceutical business model. The effective tax rate for the period was approximately 32.1%, resulting in an income tax expense of $150.0 million.
Halozyme exhibited exceptional cash generation capabilities, with net cash provided by operating activities totaling $651.6 million. After accounting for capital expenditures of $7.0 million, free cash flow approximated $644.6 million. The balance sheet reflects a strategic shift towards leverage to fund acquisitions. Long-term debt stood at $2.14 billion, significantly outweighing total stockholders' equity of $48.8 million. The company raised $1.47 billion in proceeds from convertible debt while repaying $845.4 million in convertible notes. Cash and cash equivalents ended the year at $133.8 million, with total liquidity supported by strong operating cash flows.
The financial activities in FY 2025 indicate a strategic pivot towards aggressive expansion through acquisition, evidenced by the $726.0 million acquisition of a business and $287.8 million for in-process R&D. The company's substantial investment in intangible assets ($981.5 million net) and goodwill ($580.4 million) suggests management is positioning for long-term value creation through its pipeline and acquired technologies. While specific forward-looking guidance figures were not provided in the source text, the refinancing activities and share repurchase program ($342.4 million) signal management's confidence in future cash flow generation and a commitment to shareholder returns.